Medicine boxes and price arrows on an India map.
Novo Nordisk has significantly reduced the prices of its diabetes and obesity drugs, Ozempic and Wegovy, in India, responding to increased competition in the GLP-1 market. Effective April 1, the prices have been slashed by 36% for Ozempic and 48% for Wegovy, according to an announcement by the company.
The move aims to enhance patient access to these therapies, making them more affordable for individuals managing diabetes and obesity. The price reduction coincides with the entry of Indian companies into the market with generic versions of semaglutide, following the expiration of key patents.
This pricing strategy reflects Novo Nordisk’s efforts to maintain market share amid growing competition. The availability of generic alternatives is expected to further drive down the costs of semaglutide treatments in India, benefiting a larger segment of the population.
About the Author
